New drug cocktail tested for Tough-to-Treat blood cancers
NCT ID NCT02296918
Summary
This early-stage study tested the safety and initial effectiveness of combining the drug acalabrutinib with other cancer medications for patients with chronic lymphocytic leukemia (CLL) and related blood cancers. It involved 69 patients, some who had been treated before and some who were newly diagnosed. The main goal was to see how safe the drug combinations were and to get a first look at whether they helped control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.